Published in Neurosci Lett on February 04, 2009
Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One (2010) 1.41
Expression and localization of mitochondrial ferritin mRNA in Alzheimer's disease cerebral cortex. PLoS One (2011) 0.84
A computational procedure for functional characterization of potential marker genes from molecular data: Alzheimer's as a case study. BMC Med Genomics (2011) 0.82
Diverse and pervasive subcellular distributions for both coding and long noncoding RNAs. Genes Dev (2016) 0.80
Gene expression profiling in cells with enhanced gamma-secretase activity. PLoS One (2009) 0.78
Lactoferrin and prematurity: a promising milk protein? Biochem Cell Biol (2016) 0.75
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med (1969) 5.12
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A (1997) 3.47
RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci (1999) 2.86
Radical AGEing in Alzheimer's disease. Trends Neurosci (1995) 2.32
Lactoferrin and transferrin: a comparative study. Biochim Biophys Acta (1972) 2.13
Lactoferrin--a multifunctional protein with antimicrobial properties. Mol Immunol (2003) 1.97
Lactoferrin: a general review. Haematologica (1995) 1.89
Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J (1981) 1.85
A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res (1992) 1.69
Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (1988) 1.65
In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem (2000) 1.60
The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol (1998) 1.55
Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med (1999) 1.55
Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol (2000) 1.31
Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood (1992) 1.30
Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol (1993) 1.26
Modulation of classical C3 convertase of complement by tear lactoferrin. Immunology (1982) 1.25
Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem (1999) 1.15
Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol (1993) 1.09
Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J Infect Dis (1992) 1.09
Antiinflammatory activities of lactoferrin. J Am Coll Nutr (2001) 1.04
Structure and biological actions of lactoferrin. J Mammary Gland Biol Neoplasia (1996) 1.01
Three-dimensional structure of lactoferrin in various functional states. Adv Exp Med Biol (1994) 0.91
Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin. Immunology (1985) 0.89
The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res (1994) 0.87
Prooxidant activity of transferrin and lactoferrin. J Exp Med (1990) 0.85
Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol (1996) 0.82
Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Immunopharmacology (1997) 0.81
Tumor necrosis factor-alpha increases lactoferrin transcytosis through the blood-brain barrier. J Neurochem (1999) 0.79
Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res (2001) 0.79
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging (2011) 3.83
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant (2013) 2.71
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol (2003) 2.36
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord (2014) 2.17
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail (2005) 1.99
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med (2003) 1.79
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Alzheimer's disease a century later. J Clin Psychiatry (2006) 1.74
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Dispatcher-assisted cardiopulmonary resuscitation: risks for patients not in cardiac arrest. Circulation (2009) 1.71
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Functional anatomy of the basal ganglia in X-linked recessive dystonia-parkinsonism. Ann Neurol (2005) 1.70
Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol (2010) 1.69
Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (2006) 1.64
Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet (2007) 1.62
Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging (2008) 1.60
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis (2006) 1.58
Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation (2012) 1.57
Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg (2010) 1.57
Brain biochemistry in autopsied patients with essential tremor. Mov Disord (2011) 1.56
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis (2010) 1.54
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol (2007) 1.53
Transition metal abnormalities in progressive dementias. Biometals (2011) 1.51
An association with great implications: vascular pathology and Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 1.50
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One (2009) 1.49
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank (2010) 1.46
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol (2011) 1.45
Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord (2010) 1.42
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med (2007) 1.38
Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci (2002) 1.36
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol (2013) 1.34
Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J Neurosci (2004) 1.33
Sorl1 as an Alzheimer's disease predisposition gene? Neurodegener Dis (2007) 1.31
Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res (2004) 1.28
Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant (2013) 1.27
Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron (2013) 1.26
Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J Neurosci Res (2010) 1.26
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion (2006) 1.25
Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. Psychosom Med (2013) 1.24
Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging (2005) 1.24
Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging (2008) 1.24
Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol (2006) 1.23
Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol (2010) 1.22
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation (2006) 1.20
Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis (2007) 1.20
CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. Neurobiol Aging (2004) 1.19
Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology (2014) 1.19
Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol (2012) 1.18
Low-dose dobutamine tissue-tagged magnetic resonance imaging with 3-dimensional strain analysis allows assessment of myocardial viability in patients with ischemic cardiomyopathy. Circulation (2006) 1.18